Drug Profile
ASP 4058
Alternative Names: ASP-4058Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Astellas Pharma
- Class Neuropsychotherapeutics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Multiple sclerosis
Most Recent Events
- 02 Nov 2012 Discontinued - Phase-I for Multiple sclerosis in USA (PO)
- 01 Aug 2011 Phase I development in Multiple sclerosis is ongoing in the US
- 02 Aug 2010 Phase-I clinical trials in Multiple sclerosis in USA (PO)